Sage Journals: Discover world-class research

Abstract

The paper examines the welfare properties of an ex post value regulation scheme in which a pharmaceutical firm's revenue varies with the social value of its product. The mechanism, which is a variant of that proposed by Loeb and Magat, leads to efficient investment in research and development (R&D), production, consumption, and pro motion under certain market and technologic conditions. The mechanism's attractive simplicity is lost when account is taken of the rivalrous nature of R&D, the fact that drugs can be complements or substitutes, the excess cost of taxes needed to finance the mechanism, and the multinational character of most pharmaceutical firms. Key words: pharmaceuticals; reimbursement; pharmacoeconomics; price regulation; public policy. (Med Decis Making 1998;18 suppl:S27-S38)

Get full access to this article

View all access options for this article.

References

Gravelle Hse. Ex post value regulation of pharmaceutical prices . In: Arestis P , Daniel S , Grahl J (eds). Regulation, Strategies and Policies: Essays in Microeconomics in Honour of Bernard Corry and Maurice Peston. London, U.K.: Edward Elgar, 1998.

Bloor K. , Maynard A. , Freemantle N. Lessons from international experience in controlling pharmaceutical expenditure. III: Regulating industry. BMJ. 1996;313:33-5.

Loeb M. , Magat WA A decentralized method for utility regulation. Journal of Law and Economics. 1979;22:399-404.

Kremer M. A mechanism for encouraging innovation. Harvard Institute for International Development Discussion Paper, no. 533, May 1996.

Laffont JJ , Tirole J. A Theory of Incentives in Procurement and Regulation, Cambridge, MA: MIT Press, 1993.

Arrow KJ Uncertainty and the welfare economics of medical care. American Economic Review. 1963;53:941-73.

Drummond M. , et al. Economic evaluation of pharmaceuticals : a European perspective . PharmoEconomics. 1993;4: 173-86.

Drummond M. , Jonsson B. , Rutten F. The role of economic evaluation in the pricing and reimbursement of medicines . Health Policy 1997;40:199-215.

Vickrey W. Automobile accidents, tort law, externalities and insurance. Journal of Law and Contemporary Problems. 1968:33:464-87.

10.

Earl-Slater A. Regulating the price of the UK's drugs. BMJ. 1997;314:365-8.

11.

Towse A (ed). Guidelines for the Economic Evaluation of Pharmaceuticals: What Can the UK Learn from Australia and Canada? London, U.K.: Office of Health Economics, 1997.

Ex post Value Reimbursement for Pharmaceuticals

Abstract

Get full access to this article

References